Drug Approval | April 01, 2025
Morepen secures Loratadine approval for export to China
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Positions Curium as leading manufacturer of Lu-177 isotope
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Subscribe To Our Newsletter & Stay Updated
